Situation professionnelle actuelle (02.2024):

2022- ongoing Service de Cardiologie, consultant externe

Clinique Saint Pierre, 1340 Ottignies

Consultation de cardiologie générale

CM de Wavre,

2012- ongoing Comité d’Ethique

Clinique St Pierre , 1340 Ottignies

2015 – ongoing Centre de Cardiologie Charlemagne

Avenue de l’Union Européenne, 16

1348 Louvain La neuve

Cardiologie générale, insuffisance cardiaque, échographie.

Expérience professionnelle :

2009 - 2022: Service de Cardiologie, médecin hospitalier

Clinique Saint Pierre, 1340 Ottignies

Cardiologie générale, insuffisance cardiaque, échographie, Coro CT, recherche clinique.

2013-2016 Coordinateur Médical Brussels Heart Center

Clinique St Jean

1000 Bruxelles

1989-2009 : Service de Soins Intensifs

Clinique Saint-Pierre, 1340 Ottignies

1999-2005 : Médecin Chef de Service

2009-2016 Activité de gardes

1989-2000 : Cardiologie interventionnelle (1dj /semaine).

Cliniques St Luc - 1200 Bruxelles

Expérience en cardiologie :

Coronarographie, 1990-2008, CSPO

Cardiologie Interventionnelle, 1989-2000, CUSL

Scan coronaire, 2009-2022

Recherche clinique,1993-2018

Clinique de l’insuffisance cardiaque CSPO, 2018-2023

Ethique biomédicale :

Membre du Comité d’Ethique, CSPO, 2006

Président du Comité d’Ethique, CSPO, 2012- ongoing

Sociétés scientifiques :

Membre du Belgian interdisciplinary working group on acute cardiology (BIWAC), 1998- 2023

Membre du Belgian Working group on heart failure, 2018 - ongoing

Membre de la Société Européenne de Cardiologie, 2012- ongoing

Membre de la Société Européenne de Cardiologie, HFA, 2008- ongoing

Enseignement et Formations :

Enseignement secondaire :

1969 - 1975 Humanités Gréco-Latines, Collège Saint-Michel, 1040 Bruxelles.

Enseignement universitaire et postuniversitaire:

Etudes de Médecine : 1975 - 1982

Université Catholique de Louvain

Faculté de Médecine de Louvain-en-Woluwe, 1200 Bruxelles.

Spécialisation en Cardiologie : UCL 1982-1987

Spécialisation en Soins Intensifs : UCL 1987-1989

1987 - 1988 Hôpital Cantonal et Universitaire, Genève

1988 – 1989 Cliniques Universitaires St-Luc, Bruxelles

Formation en éthique biomédicale

1995-2000 Universite Catholique de Lille

Centre d’Ethique Médicale, D. Jacquemin.

2016-2017 Certificat Universitaire en Ethique et Soins de Santé (CUESS), Prof M. Dupuis et L. Ravez

Université de Namur.

Diplômes et agréation:

1982 Docteur en Médecine, Chirurgie et Accouchements, UCL,

1987 Spécialiste en Cardiologie, UCL

1989 Certificat de Médecine Intensive et d'Urgences, UCL

1997 Compétence légale Medecine Intensive, renouvellée en 2002, 2007 puis à titre définitif en 2012.

2017 Certificat Universitaire en Ethique et Soins de Santé (CUESS),

Expérience en recherche clinique :

Soins intensifs : études en cardiologie aiguë, 1993-2008
BHC : responsable du secteur de recherche clinique : 2009-2018.

Participation aux études cliniques :

1.- GUSTO I :

Global utilization of streptokinase ant t-PA for occluded arteries I.

NEJM 1993,329:673-82.

2.- GUSTO II :

Global use of strategies to open occluded coronary arteries II.

Circulation 1994;90:1631-7.

NEJM 1996;335/775-82.

3.- OPUS-TIMI 16 :

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial.

AHA, novembre 1999.

Circulation. 2000 Jul 11;102(2):149-56.

4.- IN TIME II :

Intravenous nPA for treatment of infarcting myocardium early.

Eur Heart J, 2000;21:2005-2013.

5.- ASSENT 2 TRIAL

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.

Lancet. 1999 Aug 28;354(9180):716-22.

6.- EXTRACT–TIMI 25

Enoxaparin andThrombolysis Reperfusion for AcuteMyocardial Infarction Treatment—Thrombolysis in Myocardial Infarction 25.

NEJM,2006, 1-12

7. OAT trial:

Coronary intervention for persistent occlusion after myocardial infarction

N Engl J Med. 2006 Dec 7;355(23):2395-407. Epub 2006 Nov 14.

8.- MERLIN-TIMI 36

Effects of Ranolazine on Recurrent Cardiovascular Events in Patients With Non–ST-Elevation acute coronary syndromes

JAMA. 2007;297(16):1775-1783

9.- IMPROVE-IT trial : investigateur principal

A multicenter, double blind, randomized study to establish the clinical benefit and safety of Vytorin ( Ezetimibe/simvastatin tablet) vs Simvastatin monotherapy in high risk subjects presenting with acute coronary syndrome.

ongoing

Schering-Plough 2009

10.- PEGASUS TIMI 54 trial: investigateur principal

A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction

Astra-Zeneca 2011-2013

11. EPICOR :

Registre syndromes coronariens aigus.

Astra Zeneca 2010-2011

12. PARADIGM trial:

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction

Novartis 2010

13. CANTOS trial: investigateur principal

A randomized, double-blind, placebo-controlled, event driven trial of quarterly subcutaneous canakinumab in theprevention of recurrent cardiovascular events amongstable post-myocardial infarction patients with elevated hsCRP

Novartis 2012.

14. MEDCOR trial:

Double-blind parallel placebo-controlled study to evaluate the effect of Molsidomine on the Endothelial Dysfunction in patients with stable angina pectoris undergoing a percutaneous Coronary intervention.

Therabel Pharma 2012

15.- ODYSSEY trial, investigateur principal

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the

Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients who have Recently Experienced an Acute Coronary Syndrome.

Ongoing 2013-2015

Sanofi

16.- Ivabradine in HF-PEF, investigateur principal

Effects of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation, in patients with Chronic Heart Failure and Preserved left ventricular Ejection Fraction

2013

Servier

17.- Paragon: investigateur principal

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate

the efficacy and safety of LCZ696 compared to valsartan on morbidity and mortality in patients with chronic heart failure and preserved ejection fraction

Ongoing , 2015

Novartis

Travaux scientifiques

1.- Publications

1.- Pirenne B, Marchandise B :

Electrocardiogramme et hypothermie.

Arch. Mal. Coeur. 1988.81:1017-1020.

2.- Bohon Ph. Dugernier T, Debongnie JC, Pirenne B.

Pneumopathie interstitielle d'hypersensibilité et recto-colite ulcéro-hémorragique : rôle du methotrexate.

Acta Gastroente Bel 1993,56:352-7.

3.- Col J, Pirenne B, Decoster O, Payen B, Deligne B, Purnode P, Bachy JL, Renkin J.

Basic components and patterns of acute ischemia recovery assessed from continuous ST monitoring in acute myocardial infarction treated by thrombolytic therapy.

Journal of Electrocardiology. 1994:27 supplement, 241-248.

4.- Amrani M, Rubay J, Pirenne B, Col J, Dion R.

Isolation of the left coronary artery ostium by an aortic cusp attachment : a rare cause of myocardial ischemia.

Eur J Cardio-thorac Surg, 1994 8:663-664.

5.- Renkin J, Pirenne B, Carlier M, Col J.

Traitement de l'infarctus du myocarde. Thrombolyse ou angioplastie ?

Louvain Médical 1995 114:223-6.

6.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J :

Rapid detection of streptokinase resistance using a bedside lytic assay of dry recipent technology.

Fibrinolysis and Proteolysis, 2000,14(6);1-7.

7;- Honoré PM, Jamez J, Wauthier M, Lee PA, Dugernier T,Pirenne B,Hanique G, Matson JR.

Prospective evaluation of short term, high volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure from septic shock.

Crit Care Med 2000 Nov;28 (11): 3581-7. 12.-

8,- R. Colenbunders, J.L. Mariage,J.CH Coche, B. Pirenne, S. Kempinaire, Ph. Hantson, A. Van Gompel, M. Niedrig, M. Van Esbroeck, R. Bailey, C. Drosten, and H. Scmitz:

A belgian traveler who acquired yellow fever in the gambia.

Clin; Infect; Dis. 2002, Nov 15;35 (10): e113-6. Epub 2002 Oct 28.

9,- Kamal A. Al Shawafi, Antoine de Meester, Bruno Pirenne, Jacques J. Col.

Comparative fibrinolytic activity of front-loaded alteplase and the single bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.

Am Heart J 2003; 145:217-25.

10. Double-Blind Parallel Placebo-Controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients with Stable Angina Pectoris Undergoing Percutaneous Coronary Intervention: the MEDCOR Trial.

Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W.

J Cardiovasc Transl Res. 2013 Oct 19. [Epub ahead of print]

11. Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W.

Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial.

J Cardiovasc Transl Res. 2014 Mar;7(2):226-31. doi: 10.1007/s12265-013-9513-9. Epub 2013 Oct 19.

2.- Abstracts

1.- Pirenne B, Bruchner JC, Suter PM :

Intérêt de la mesure de la dépense énergétique en médecine intensive. Assemblée Annuelle Suisse de Médecine Intensive. Montreux, 1988.

Schweiz. Med. Wschr 1989;119:384.

2.- Palazzo M, Pirenne B, Morel DR, Suter PM :

Relationship between O2 consumption and O2 delivery in severely ill patients with reference to their hormonal status and outcome.

Assemblée Annuelle Suisse de Médecine Intensive. Montreux, 1988.

Schweiz. Med. Wschr 1989;119:380.

3.- Col J, Decoster O, Hanique G, Deligne B, Boland J, Pirenne B, Cheron P, Renkin J :

Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction : results of double blind randomized stury (OSIRIS).

American Heart Association, New Orleans, novembre 1992. Circulation 86, I 259, 1992.

4.- Decoster O, Boland J, Pirenne B, Cheron P, Renkin J, Col J :

Recovery patterns obtained from continuous ST segment monitoring during thrombolysis for acute myocardial infarction are good predictors for coronary recanalization. American College of Cardiology, Anaheim, Mars 1993.

JACC 21,459A, 1993.

5.- Decoster O, Renkin J, Boland J, Pirenne B, Cheron P, Col J.

Recovery patterns obtained from continuous ST segment monitoring during thrombolysis for acute myocardial infarction are accurate Predictor for successful myocardial reperfusion. European Society of Cardiology, Nice, Septembre 1993.

Eur. Heart J, 1993 14:354.

6.- Col J, Al Shwafi K, Pirenne B, Renkin J, Van de Werf F.

Analysis of continuous ST-segment monitoring as a surrogate to coronary angiograms for assessing thrombolytic efficacy. Application in the GUSTO trial. Annual scientific meeting of the Belgian Society of Cardiology, Brussels, February 1996.

Acta Cardiologica Belgica, 1996, 51(1), 44.

7.- Al Shwafi K, Col J, Pirenne B, de Meester A, Miesse C, Renkin J :

Lytic activity with accelerated t-PA assessed at bedside during thrombolytic therapy for acute myocardial infarction.

JACC, 1997,29(2), 1034-54,1997.

Thrombosis and hemostasis, 1997:suppl june:502.

8.- Col J, Al Shwafi K, Pirenne B, de Meester A, Miesse C, Renkin J.

Lytic activity profile of 1.5 MU streptokinase infused in 6O minutes for acute myocardial infarction. European Society of Cardiology.

August 24-28, 1997. Stockholm - Sweden.

Eur. Heart Journal, 1997, 18(suppl.), 634.

9.- de Meester A, Al Shwafi K, Pirenne B, Miesse C, Renkin J, Col J.

Comparison of lytic activities during accelerated t-PA and streptokinase infusion in patients treated for acute myocardial infarction. European Society of Cardiology. August 24-28, 1997. Stockholm - Sweden.

Eur. Heart Journal. 1997,18(suppl.),634.

10.- Al Shwafi K, de Meester A, Pirenne B, Miesse C, Renkin J, Col J.

Comparative lytic activity profiles of accelerated infusion of t-PA and 30 mgr bolus of TNK-tPA. European Society of Cardiology. August 24-28, 1997. Stockholm - Sweden.

Eur. Heart Journal, 1997, 18(suppl), 633.

11.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J.

Rapid establishment of intense lytic activity with t-PA correlates with early ST elevation resolution as predictor of outcome after AMI.

Circulation, 1997 : 96,8(supplément):260.

12.- Vranckx P, Al Shwafi K, de Meester A, Pirenne B, Jacquet L, Renkin J, Col J.

In vitro lytic response to 1OO U/ml streptokinase predicts ECG response to standard dose of streptokinase for AMI.

Circulation, 1997 : 96,I 260:1445.

13.- de Meester A; Al Shwafi K, Pirenne B, Vranckx P, Renkin J et Col J.

In-vitro streptokinase resistance test for rapid prediction of coronary artery patency using continuous ST-segment monitoring during acute myocardial infarction.

Acta Cardiologica Vol LII, 1997:6:556-557.

14.- de Meester A; Al Shwafi K, Pirenne B, Vranckx P, Renkin J et Col J.

The thrombolytic response early during the 60-minutes infusion of 1.5 MU streptokinase determined the extent of ST segment resolution in patients with acute myocardial infarction.

Acta Cardiologica Vol LII,1997:6:543-544.

15.- Al Shwafi K, de Meester A, Pirenne B, Vranckx P, Renkin J, Col J.

Rapid clot lysis test predicts lytic response to streptokinase therapy for acute myocardial infarction. European Society of Cardiology, August, 22-26, 1998, Vienna.

Eur Heart J, 1998,19:280.

J Am Coll Cardiol 1998:31, suppl C:454.

16.- Al Shwafi K, de Meester A, Pirenne B et al. Rapid clot lysis test predicts lytic response to streptokinase therapy for acute myocardial infarction.

J Am Coll Cardiol 1998:31:454.

17.- Al Shwafi K, de Meester A, Pirenne B, Renkin J, Col J.

Bedside lytic activity assessment during accelerated tPA and TNK-tPA therapy for acute myocardial infarction.

J Am Coll Cardiol 1998;31:452A.

18.- de Meester A, Al Shwafi K, Pirenne B et al.

In vitro streptokinase test for rapid prediction of coronary artery patency by angiography after acute myocardial infarction.

Eur Heart J 1999.

19.- Al Shafi K, de Meester A, Pirenne B, Vranckx P, Renkin J, Col J.

Evaluation of a rapid bedside test for streptokinase resistance applied in acute myocardial infarction (abstract). Eur Heart J 1999;20(suppl):516.

20. Emanuele Barbato, Arnold Herman , Edouard Benit , Luc Janssens , Jacques Lalmand , Etienne Hoffer

Patrick Chenu , Antoine Guedes , Luc Missault ,Bruno Pirenne , François Cardinal, Steven Vercauteren , William Wijns .

Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: Results of the MEDCOR trial.

Atherosclerosis 240 (2015) 351e354